Company Overview
Company Type: Public Company
Website: www.valeopharma.com
Number of Employees: 125
Ticker: VPH (TSX)
Year Founded: 2003


Business Description
Valeo Pharma Inc., a specialty pharmaceutical company, engages in the acquisition, in-licensing brands, and sale of pharmaceuticals and hospital specialty products for unmet medical needs in Canada. Its product portfolio includes Enerzair Breezhaler, an LABA/LAMA/ICS fixed triple dose asthma drug; Atectura Breezhaler, an LABA/ICS dual combination asthma drug; Redesca, to treat and prevent deep vein thrombosis and pulmonary embolism; Onstryv, Idiopathic Parkinson’s Disease (PD) as an add-on for patients on stable dose of Levodopa alone or in combination with other drugs; M-Eslon, extended-release morphine sulphate used for pain management; and Yondelis, a soft tissue sarcoma. It also offers Hesperco, bioflavonoid antioxidant used for immune support; Ametop, for skin Anesthesia prior to venepuncture or venous cannulation; Benztropine, an VPI-Anticholinergic agent used for the treatment of PD; Ethacrynate Sodium, a loop diuretic for high blood pressure and associated swelling; and Amikacin, an injectable antibiotic. In addition, the company provides Ametop Gel 4%, for skin anesthesia prior to injection or cannulation; Sabizabulin, oral dual antiviral/anti-inflammatory agent for high-risk hospitalized adults suffering from covid-19; Simbrinza, ophthalmic drops to treat openangle glaucoma or ocular hypertension; Xiidra, an prescription based eye-drop to treat dry eye disease; and Allerject, a portable voice-activated epinephrine injector for emergency treatment of serious allergic reactions. Its primary therapeutic areas include respiratory / allergy, ophthalmology, and specialty and hospital generic products. Valeo Pharma Inc. was incorporated in 2003 and is headquartered in Kirkland, Canada.

Financial Information (Currency: CAD, in mm) 
Total Revenue
53.5
Market Capitalization
18.7
TEV/Total Revenue
1.4x
EBITDA
(12.0)
Total Enterprise Value
73.1
TEV/EBITDA
NM
EBIT
(13.9)
Cash & ST Invst.
9.8
P/Diluted EPS Before Extra
NM
Net Income
(27.9)
Total Debt
64.1
Price/Tang BV
NM
Capital Expenditure
(0.5)
Total Assets
45.5
Total Debt/EBITDA
NM
Currency in CAD in mm, LTM as of Jul-31-2023 TEV and Market Cap are calculated using a close price as of Oct-06-2023


Estimates & Guidance Snapshot (Current Fiscal Year End: Oct-31-2023 | Currency: CAD)
Periodic Estimates
Current FQ
Guidance Current FQ
Current FY
Guidance Current FY
NTM
EPS (GAAP)
(0.05)
-
(0.25)
-
(0.15)
Revenue (mm)
16.78
-
57.58
56.00 - -
74.58
EBITDA (mm)
(0.81)
-
(7.19)
-
0.99

Forward Multiples (Current FY)

Price/Earnings
NM
TEV/REV
1.26x
TEV/EBITDA
NM
P/BV
NM

Non-Periodic Estimates

Recommendation
Buy (1.33)
Target Price
0.72
Potential Upside
287.39%


Key Professionals
Name
Title
Saviuk, Steven 
Vice Chairman, President & CEO
Mainville, Luc 
Senior VP & CFO
Dumais, Frederic 
Director of Communications & Investor Relations
Allard, Guy-Paul 
VP of Legal Affairs & Corporate Secretary
Fournier, Jean Francois
Head of Ophthalmology Business Unit
Steiger, Kyle 
Senior VP & Chief Commercial Officer

Key Board Members
Name
Title
MacKay, Richard J.
Chairman of the Board & Chairman of the Advisory Board
Saviuk, Steven 
Vice Chairman, President & CEO
Leger, Marc F.
Independent Non-Executive Director
Brennan, Maureen C.
Independent Director
Close, Tamara 
Director
Fowler, Stuart W.
Director
Leconte, Didier 
Director
Trudeau, Michel Claude
Independent Director


Primary Industry Classification
Health Care Distributors


Primary Office Location
16667 Hymus Boulevard | Kirkland, QC | H9H 4R9 | Canada
Phone: 514-694-0150   Fax: 514-694-0865

Current and Pending Investors
Investissement Québec, Manitex Capital Inc. (TSXV:MNX), Sagard Holdings ULC

Stock Quote and Chart (Currency: CAD)
Last  (Delayed)
 0.19
Market Cap (mm)
18.2
Open
 0.20
Shares Out. (mm)
98.6
Previous Close
 0.19
Float %
46.8%
Change on Day
(0.01)
Shares Sold Short (mm)
-
Change % on Day
(2.6)%
Dividend Yield %
-
Day High/Low
 0.20/ 0.19
Diluted EPS Excl. Extra Items
(0.33)
52 wk High/Low
 0.69/ 0.19
P/Diluted EPS Before Extra
NM
Volume (mm)
0.03
Avg 3M Dly Vlm (mm)
0.03
Beta 5Y
2.58


 
Delayed Quote** | Last Updated on Oct-10-2023 12:00 AM (GMT-5)
TSX:VPH - Common Stock


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Aug-31-2023
Aug-31-2023
Private Placement
Target
Valeo Pharma Inc. (TSX:VPH)
Investissement Québec

3.32
Dec-09-2021
Jan-13-2022
Private Placement
Target
Valeo Pharma Inc. (TSX:VPH)


0.80
Nov-24-2021
-
Private Placement
Target
Valeo Pharma Inc. (TSX:VPH)
Investissement Québec

19.44
Nov-24-2021
Nov-24-2021
Public Offering
Target
Valeo Pharma Inc. (TSX:VPH)


11.84
Jun-8-2021
Jun-29-2021
Public Offering
Target
Valeo Pharma Inc. (TSX:VPH)


8.08
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Sep-27-2023
Debt Financing Related
Valeo Pharma Enters into $5 Million Credit Facility Agreement with Accord Financial Inc
Sep-14-2023
Earnings Calls
Valeo Pharma Inc., Q3 2023 Earnings Call, Sep 14, 2023
Aug-31-2023
Private Placements
Valeo Pharma Inc. announced that it has received CAD 4.499999 million in funding from Investissement Québec
Jun-22-2023
Executive/Board Changes - Other
Valeo Pharma Inc. Announces Board Appointments
Jun-14-2023
Earnings Calls
Valeo Pharma Inc., Q2 2023 Earnings Call, Jun 14, 2023

Competitors
Bausch Health Companies Inc. (NYSE:BHC), HLS Therapeutics Inc. (TSX:HLS), Knight Therapeutics Inc. (TSX:GUD), Searchlight Pharma Inc.


Advisors
Most Recent Auditor
PricewaterhouseCoopers LLP
Private Placement Advisors
Desjardins Capital Markets
Public Offering Advisors
McMillan LLP, MNP LLP, PricewaterhouseCoopers LLP, Canada


Most Recent Auditor
PricewaterhouseCoopers LLP


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
Echelon Wealth Partners Inc.
Quenneville, Stefan
Sep 14, 2023 12:33 PM
VPH
VPH - Despite Strong Growth FQ3 Misses Expectations; Trimming Target on Uncertainty Over Xiidra; Maintaining Spec. Buy Rating
EPS Estimates*
6
Research Capital Corporation
Uddin, Andre
Sep 14, 2023 08:32 AM
VPH
Weak Q3 - Under Pressure - Lowering Target Price
Ratings Change*
7
GlobalData

Sep 12, 2023 03:43 AM
VPH
Valeo Pharma Inc (VPH.TSE) - Financial Analysis Review
Reports
133
Echelon Wealth Partners Inc.
Quenneville, Stefan
Sep 01, 2023 05:38 AM
VPH
VPH - $4.5M Financing Provides Working Capital for Rapidly Growing Business; Maintaining Spec. Buy Rating and PT
Notes
5
GlobalData

Aug 23, 2023 06:42 AM
VPH
Valeo Pharma Inc (VPH.TSE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
54
Research Capital Corporation
Uddin, Andre
Jul 04, 2023 11:00 AM
VPH
A Fork In The Road
Reports
4
Paradigm Capital, Inc.
McAuley, Scott
Jun 15, 2023 06:47 PM
VPH
VPH: Q2/FY23 Earnings
EPS Estimates*
8
Research Capital Corporation
Uddin, Andre
Jun 14, 2023 07:48 AM
VPH
Q2 - Investors Await The Turn - H2 Should Be Strong
Reports
7
GlobalData

Jun 09, 2023 05:02 AM
VPH
Valeo Pharma Inc (VPH.TSE) - Financial Analysis Review
Reports
128
Paradigm Capital, Inc.
McAuley, Scott
May 25, 2023 07:33 PM
VPH
VPH: In-line Q2 Financial Guidance
Notes
5


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


Manitex Capital Inc.

23,322,987

23.65

4.4

Sep-25-2023


MacKay, Richard J.

16,222,751

16.45

3.1

Aug-31-2023


Mainville M.B.A, M.B.A., Luc 

3,041,055

3.08

0.6

Sep-25-2023


Saviuk CA, Helen 

2,568,324

2.60

0.5

Jan-27-2023


Leger, Marc F.

2,331,414

2.36

0.4

Apr-27-2023


Simcor Canada Holdings, Inc.

1,694,145

1.72

0.3

Sep-20-2023


Therrien, Nathalie 

1,358,369

1.38

0.3

Mar-15-2023


Trudeau, Michel Claude

641,972

0.65

0.1

Apr-27-2023


Hogue M.Sc., MSc, Vincent P.

517,323

0.52

0.1

Feb-27-2023


Allard, Guy-Paul 

400,071

0.41

0.1

Aug-31-2023



 



Top Buyers
Buyers
Common Stock Equivalent Held
Change
MacKay, Richard J.
16,222,751
4,178,571
Mainville M.B.A, M.B.A., Luc 
3,041,055
750,000
Trudeau, Michel Claude
641,972
37,037
Leger, Marc F.
2,331,414
27,778
Brennan, Maureen C.
27,778
27,778

Top Sellers
Sellers
Common Stock Equivalent Held
Change
Skinner, Jeff 
0
(1,402,150)
Simcor Canada Holdings, Inc.
1,694,145
(520,000)
Manitex Capital Inc.
23,322,987
(507,143)


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
Date/Time
Headline
Source
Sep-13
VPH Valeo Pharma loses $5.8-million in Q3 2023
Canada StockWatch
Sep-13
VALEO PHARMA REPORTS RECORD THIRD QUARTER 2023 REVENUES
Canada Newswire


Company Coverage
This company is not on any Coverage List.

Products
Ametop Gel, Distribution of Amikacin, Distribution of Atectura Breezhaler, Distribution of Benztropine, Distribution of Enerzair Breezhaler, Distribution of M-Eslon, Distribution of Ondansetron ODT, Distribution of Onstryv, Distribution of Pharmaceutical Products, Distribution of Pip-Tazo, Distribution of Redesca, Distribution of Synacthen, Distribution of Utrogestan, Distribution of Yondelis, Ethacrynate Sodium, Hesperco, Sabizabulin (Future)


Upcoming Events
Date/Time
Type
Dec-22-2023
Estimated Earnings Release Date (S&P Global Derived)
* Future Events are subject to change.


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Source
Form Type
Language
Size
Oct-04-2023
-
Valeo Pharma Inc. (TSX:VPH)
SEDAR
News Releases
English
29 KB
Sep-27-2023
-
Valeo Pharma Inc. (TSX:VPH)
SEDAR
News Releases
French
27 KB
Sep-27-2023
-
Valeo Pharma Inc. (TSX:VPH)
SEDAR
News Releases
English
26 KB
Sep-13-2023
Jul-31-2023
Valeo Pharma Inc. (TSX:VPH)
SEDAR
Interim Financial Statements
English
411 KB
Sep-13-2023
Jul-31-2023
Valeo Pharma Inc. (TSX:VPH)
SEDAR
Interim Financial Statements
English
1 MB
Sep-13-2023
-
Valeo Pharma Inc. (TSX:VPH)
SEDAR
News Releases
French
45 KB
Sep-13-2023
-
Valeo Pharma Inc. (TSX:VPH)
SEDAR
News Releases
English
43 KB
Sep-07-2023
-
Valeo Pharma Inc. (TSX:VPH)
SEDAR
News Releases
English
33 KB
Sep-01-2023
-
Valeo Pharma Inc. (TSX:VPH)
SEDAR
Securities Acquisition Filings (Early Warning)
English
157 KB
Sep-01-2023
-
Valeo Pharma Inc. (TSX:VPH)
SEDAR
Securities Acquisition Filings (Early Warning)
English
157 KB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Mainville M.B.A, M.B.A., Luc  (Senior VP & CFO)
Sep-25-2023
Class A Shares
650,000
-
Other Acquisition
27.18
Multiple
Manitex Capital Inc.
Sep-25-2023
Class A Shares
650,000
-
Other Acquisition
2.87
Multiple
Manitex Capital Inc.
Sep-25-2023
Class A Shares
650,000
-
Other Acquisition
2.63
Multiple
Simcor Canada Holdings, Inc.
Sep-20-2023
Class A Shares
(520,000)
(131,848)
Private Disposition
(23.49)
Multiple
Manitex Capital Inc.
Aug-31-2023
Class A Shares
892,857
233,103
Private Acquisition
3.75
Multiple
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
MacKay, Richard J.
Chairman of the Board & Chairman of the Advisory Board
514-694-0150
514-694-0865

Saviuk, Steven 
Vice Chairman, President & CEO
514 693-8830
514-694-0865
steve@manitexcapital.com
Leger, Marc F.
Independent Non-Executive Director
514-694-0150
514-694-0865

Brennan, Maureen C.
Independent Director
514-694-0150
514-694-0865

Close, Tamara 
Director
514-694-0150
514-694-0865

Fowler, Stuart W.
Director
514-694-0150
514-694-0865
fowler_stu@allergan.com
Leconte, Didier 
Director
(514) 850-4976
514-694-0865

Trudeau, Michel Claude
Independent Director
514-350-3030
514-694-0865

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Saviuk, Steven 
Vice Chairman, President & CEO
514 693-8830
514-694-0865
steve@manitexcapital.com
Mainville, Luc 
Senior VP & CFO
(514) 693-8854
514-694-0865
mainville@orthorti.com
Dumais, Frederic 
Director of Communications & Investor Relations
(514) 782- 8803
514-694-0865
dumais@valeopharma.com
Allard, Guy-Paul 
VP of Legal Affairs & Corporate Secretary
(514) 693-8832
514-694-0865
allard@orthorti.com
Fournier, Jean Francois
Head of Ophthalmology Business Unit
514-694-0150
514-694-0865

Steiger, Kyle 
Senior VP & Chief Commercial Officer
514-694-0150
514-694-0865

* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 

**Intraday Quotes are delayed by at least 20 minutes.
